Navigation Links
The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
Date:7/16/2008

Survey Highlights Trends In eCTD Migration And Submissions Outsourcing And Provides Insights Into Regulatory Product Management Trends Across North

America And Europe

PHILADELPHIA and LONDON, July 17 /PRNewswire/ -- The Scientific business of Thomson Reuters today announced the early findings of its 2008 Liquent Regulatory Affairs Trends Survey. The survey attracted respondents from across the globe representing small, medium and large pharmaceutical companies and provides a unique insight into emerging and future trends in regulatory product management usage and adoption.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NYTH069LOGO )

Now in its sixth year and frequently sourced by pharmaceutical journals and publications across the world, this survey has become the premier benchmark of global regulatory submission trends offering timely insights into how pharmaceutical regulatory professionals use technology today and how they plan to harness technology in the future.

There were 137 Regulatory Affairs professionals working in Life Sciences companies across the globe who participated in this survey. The survey concentrates on four key areas: Technology Usage Trends, including both submission publishing software and other desktop software, Document Management System usage, Regulatory Outsourcing trends, and Regulatory trends including use or future use of the electronic Common Technical Document (eCTD).

The demographic make-up of the respondent population is similar to previous years with almost one third working in large pharmaceutical companies (32%) and more than a third working in small to medium companies (36%). Another 10% of respondents work for biotechnology companies. There were significantly more respondents from Contract Research Organizations (CROs) in 2008 (10%) than in 2007 (4%). 68% of those sur
'/>"/>

SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Principle of Recursive Genome Function Supersedes Dogmas; By Andras Pellionisz, Online Ahead of Print; (Scientific Visionary Vindicated)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
4. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
5. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
6. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
7. Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results
8. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
9. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
10. Californias International Stem Cell Collaborations Must Be Based on Scientific Merit, Consumer Group Says
11. Corgenix Expands Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... SLOUGH, England , July 29, 2015  Indivior ... Application (NDA) for naloxone nasal spray was accepted and ... Administration (FDA) for the treatment of opioid overdose. This ... contains naloxone specially formulated for optimal absorption into the ... to require minimal training so individuals may be better ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris ... announced it has selected an optimized Erk inhibitor ... in the development of a new class of ... pathway represents a prime target for therapeutic intervention ... activities and survival benefits for B-Raf and Mek ...
(Date:7/29/2015)... ... 2015 , ... Available in select spas and http://www.lespausa.com ... product that targets fat cells for extreme contouring action. During sleep key ingredient ... inhibiting the formation of new fat. Upon waking CHRONODIET breaks down fat cells’ ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3